Nilnur EYERCİ, Necmettin AKDENİZ, Sadullah KELEŞ, Eda BALKAN

miRNA expression profile in Behcet patients using colchicine

Aim: Behcet’s disease (BD) is a multi-systemic disorder which shows inflammatory vasculitis characteristic with recurrent oral aphthae, eye lesions, and genital ulceration. MicroRNA’s (miRNAs) are small non-coding RNA molecules that play an important role in the regulation of various biological processes. We aimed to determine miRNAs that are thought to be associated with inflammatory processes in BD patients using colchicine in the active period.Materials and Methods: We enrolled 24 patients with BD receiving colchicine treatment and a control group comprising 30 healthy unrelated individuals. We studied with a panel where 377 miRNAs were included in the assay.Results: miR-20a, miR-34a, miR-197, U6snRNA, miR-205, miR-222, miR-296, miR-302a, miR-302c, and miR-372 were observed up-regulated in BD. miR-518b, miR-874 were found down-regulated within the patients. These miRNAs are known to play a role in cancer-related pathways.Conclusion: In patients treated with colchicine, the change in the expression of these miRNA may give an idea of the effect on the progression of the disease. However, patients in the active period also require further studies to fully understand the role and mechanism of action of the drug.

PDF

___

1. International Team for the Revision of the International Criteria for Behcet's D. The International Criteria for Behcet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. Journal of the European Academy of Dermatology and Venereology : JEADV 2014;28:338- 47.
2. Salmaninejad A, Gowhari A, Hosseini S, et al. Genetics and immunodysfunction underlying Behcet's disease and immunomodulant treatment approaches. J Immunotoxicol 2017;14:137-51.
3. Stojanov S, Kastner DL. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Current opinion in rheumatology. 2005;17:586-99.
4. Woo MY, Cho O, Lee MJ, et al. Differential effects of colchicine in blood mononuclear cells of patients with Behcet disease in relation to colchicine responsiveness. Br J Dermatol 2012;167:914-21.
5. Aktulga E, Altac M, Muftuoglu A, et al. A double blind study of colchicine in Behcet's disease. Haematologica 1980;65:399-402.
6. Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behcet's syndrome. Semin Arthritis Rheum 2001;44:2686-92.
7. Leccese P, Ozguler Y, Christensen R, et al. Management of skin, mucosa and joint involvement of Behcet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behcet's syndrome. Semin Arthritis Rheum 2019;48:752-62.
8. Chia EW, Grainger R, Harper JL. Colchicine suppresses neutrophil superoxide production in a murine model of gouty arthritis: a rationale for use of low-dose colchicine. Br J Pharmacol 2008;153:1288-95.
9. Li Z, Davis GS, Mohr C, et al. Inhibition of LPSinduced tumor necrosis factor-alpha production by colchicine and other microtubule disrupting drugs. Immunobiology 1996;195:624-39.
10. Slobodnick A, Shah B, Krasnokutsky S, et al. Update on colchicine, 2017. Rheumatology. 2018;57:4-11.
11. Mehta A, Baltimore D. MicroRNAs as regulatory elements in immune system logic. Nat Rev Immunol 2016;16:279-94.
12. Long H, Wang X, Chen Y, et al. Dysregulation of microRNAs in autoimmune diseases: Pathogenesis, biomarkers and potential therapeutic targets. Cancer Lett 2018;428:90-103.
13. Garo LP, Murugaiyan G. Contribution of MicroRNAs to autoimmune diseases. Cellular and molecular life sciences : CMLS 2016;73:2041-51.
14. Erre GL, Piga M, Carru C, et al. Global microRNA profiling of peripheral blood mononuclear cells in patients with Behcet's disease. Clin Exp Rheumatol 2015;33:9-72.
15. Ibrahim W, Sakr BR, Obaya E, et al. MicroRNA146a expression and microRNA-146a rs2910164 polymorphism in Behcet's disease patients. Best Pract Res Clin Rheumatol 2019;38:397-402.
16. Na SY, Park MJ, Park S, et al. MicroRNA-155 regulates the Th17 immune response by targeting Ets-1 in Behcet's disease. Clin Exp Rheumatol 2016;34:56-63.
17. Puccetti A, Pelosi A, Fiore PF, et al. MicroRNA Expression Profiling in Behcet's Disease. J Immunol Res 2018;2018:2405150.
18. Zhou Q, Xiao X, Wang C, et al. Decreased microRNA-155 expression in ocular Behcet's disease but not in Vogt Koyanagi Harada syndrome. Invest Ophthalmol 2012;53:5665-74.
19. Zou J, Ji DN, Shen Y, et al. Association of Reduced Heme Oxygenase-1 with Decreased MicroRNA-196a2 Expression in Peripheral Blood Mononuclear Cells of Patients with Intestinal Behcet's Disease. Ann Clin Lab Sci 2016;46:675-9.
20. Bulur I, Onder M. Behcet disease: New aspects. Clin Dermatol 2017;35:421-34.
21. Kulaber A, Tugal-Tutkun I, Yentur SP, et al. Proinflammatory cellular immune response in Behcet's disease. Rheumatol Int 2007;27:1113-8.
22. Musabak U, Pay S, Erdem H, et al. Serum interleukin-18 levels in patients with Behcet's disease. Is its expression associated with disease activity or clinical presentations? Rheumatol Int 2006;26:545-50.
23. Oztas MO, Onder M, Gurer MA, et al. Serum interleukin 18 and tumour necrosis factor-alpha levels are increased in Behcet's disease. Z Hautkr 2005;30:61-3.
24. Geri G, Terrier B, Rosenzwajg M, et al. Critical role of IL-21 in modulating TH17 and regulatory T cells in Behcet disease. J Allergy Clin Immunol 2011;128:655- 64.
25. Chi W, Zhu X, Yang P, et al. Upregulated IL-23 and IL-17 in Behcet patients with active uveitis. Invest Ophthalmol 2008;49:3058-64.
26. Kim ES, Kim SW, Moon CM, et al. Interactions between IL17A, IL23R, and STAT4 polymorphisms confer susceptibility to intestinal Behcet's disease in Korean population. Life sciences 2012;90:740-6.
27. Hamzaoui K, Hamzaoui A, Guemira F, et al. Cytokine profile in Behcet's disease patients. Relationship with disease activity. Scand J Rheumatol 2002;31:205-10.
28. Balkan E, Bilen H, Eyerci N, et al. Cytokine, C-Reactive Protein, and Heat Shock Protein mRNA Expression Levels in Patients with Active Behcet's Uveitis. Medical science monitor : Med Sci Monit 2018;24:1511-6.
29. Salvi V, Gianello V, Tiberio L, et al. Cytokine Targeting by miRNAs in Autoimmune Diseases. Front Immunol 2019;10:15.
30. Esatoglu SN, Hatemi G. Update on the treatment of Behcet's syndrome. Intern Emerg Med 2019;14:661- 75.
31. Yurdakul S, Hamuryudan V, Yazici H. Behcet syndrome. Curr Opin Rheumatol 2004;16:38-42.
32. Li H, Ouyang XP, Jiang T, et al. MicroRNA-296: a promising target in the pathogenesis of atherosclerosis? Molecular Med 2018;24:12.
33. Reddycherla AV, Meinert I, Reinhold A, et al. miR20a inhibits TCR-mediated signaling and cytokine production in human naive CD4+ T cells. PloS one. 2015;10:e0125311.
34. Hou C, Wang D, Zhang L. MicroRNA34a3p inhibits proliferation of rheumatoid arthritis fibroblastlike synoviocytes. Mol Med Rep 2019;20:2563-70.
35. Meiler S, Baumer Y, Toulmin E, et al. MicroRNA 302a is a novel modulator of cholesterol homeostasis and atherosclerosis.Arterioscler Thromb 2015;35:323-31.
36. Abo ElAtta AS, Ali YBM, Bassyouni IH, et al. Upregulation of miR-221/222 expression in rheumatoid arthritis (RA) patients: correlation with disease activity. Clin Exp Med 2019;19:47-53.
37. Ahn SH, Ahn JH, Ryu DR, et al. Effect of Necrosis on the miRNA-mRNA Regulatory Network in CRT-MG Human Astroglioma Cells. Cancer research and treatment : Cancer Res Treat 2018;50:382-97.
38. Kolahi S, Farajzadeh MJ, Alipour S, et al. Determination of mir-155 and mir-146a expression rates and its association with expression level of TNF-alpha and CTLA4 genes in patients with Behcet's disease. Immunol Lett 2018;204:55-9.
39. Jadideslam G, Ansarin K, Sakhinia E, et al. Expression levels of miR-21, miR-146b and miR-326 as potential biomarkers in Behcet's disease. Biomark Med 2019;13:1339-48.
40. Akkaya-Ulum YZ, Balci-Peynircioglu B, Karadag O, et al. Alteration of the microRNA expression profile in familial Mediterranean fever patients. Clin Exp Rheumatol 2017;35:90-4.
41. Wang X, Peng Y, Gao J, et al. Risk of malignancy in Behcet disease: A meta-analysis with systematic review. Medicine 2019;98:17735